Speaker 1: Hi, I'm Alex Steele introducing you to the new Stock
Speaker 1: Movers podcast from Bloomberg, the show that brings you short
Speaker 1: episodes five minutes or less, covering the stocks making gains
Speaker 1: and losses in today's trading. Subscribe to Stock Movers on Apple, Spotify,
Speaker 1: or wherever you get your podcasts.
Speaker 2: Now.
Speaker 1: Here's a sample of the latest episode from our team at.
Speaker 3: Bloomberg Bloomberg Audio Studios, Podcasts, radio News.
Speaker 4: The Stock Movers podcast your roundup of companies making moves
Speaker 4: in the stock market, harnessing the power of Bloomberg data.
Speaker 2: Let's look at some stocks on the move today. We
Speaker 2: are joined by Bloomberg's Critty Gupta on a choppy pre
Speaker 2: market session for stocks as a whole creaty. That is
Speaker 2: certainly what we are seeing at the micro level. For Delta,
Speaker 2: they just reported earnings. What's the stock doing?
Speaker 3: Good morning, Good morning, Nathan. We are getting the very
Speaker 3: first inclination of companies starting to suspend their guidance. This
Speaker 3: is a really big deal. I'm having a little bit
Speaker 3: of COVID deja vus here because when you look at
Speaker 3: some of these numbers, the earnings revisions are key to
Speaker 3: that chart you've seen massive numbers, massive hits to the
Speaker 3: tech valuations. A lot of that is only if you
Speaker 3: do indeed get those earnings revisions from these companies, or
Speaker 3: like in COVID, you do get a suspension of the
Speaker 3: guide of guidance there as well. So Delta d AL
Speaker 3: is your ticker this morning, actually coming out of the
Speaker 3: gates hire by about three percent. The market is buying this,
Speaker 3: which is non traditional, giving that they're withdrawing. They're full
Speaker 3: of your guidance, calling it given current uncertainty. They're saying
Speaker 3: that growth has largely stalled. But when you look at
Speaker 3: their first quarter numbers, they are actually coming in line
Speaker 3: with expectation. So the markets buying even just that is
Speaker 3: quite something to witness because again a very non traditional
Speaker 3: reaction for really any company that would be suspending it's guidance.
Speaker 3: Let's talk about some of the other weights in this market.
Speaker 3: I think the story of the morning, your pharma stocks
Speaker 3: are taking the biggest beating this morning. I'm just going
Speaker 3: to run through the laundry list of names this morning. Nathan,
Speaker 3: if I can, Aby is top of that list. ABBV
Speaker 3: is your ticker, down just shy of four percent this morning,
Speaker 3: one hundred and sixty nine dollars to share, Abbot right
Speaker 3: on its heels, ABT down about the same margin, trading
Speaker 3: at one hundred and nineteen dollars a share.
Speaker 4: There.
Speaker 3: Then you've got Gilliad Sciences as well, Gild down about
Speaker 3: three percent. I'm seeing if their bonds are selling off
Speaker 3: in a very big way this morning. Really keep an
Speaker 3: eye on a on a stock simply because or some
Speaker 3: of the kind of bonds that are trading. Credit seems
Speaker 3: to be leading this equity market. So anything that has
Speaker 3: a massive corporate bond hit is going to be magnified
Speaker 3: in the equity market. You're seeing that with Gilliad Sciences,
Speaker 3: like I said, Gild down about three percent, Bristol Meyers
Speaker 3: squib as well, Bmy down about three percent, trading at
Speaker 3: fifty one dollars a share, and some of our favorites
Speaker 3: there Pfizer PFE down a whopping three percent, trading at
Speaker 3: twenty one dollars share. Nathan, I could go on and on.
Speaker 3: The message this morning is if you are a pharmaceutical hit,
Speaker 3: you are taking a massive hit when it comes to
Speaker 3: your stock. And a lot of this is lead actually
Speaker 3: by some of the pain you've seen right here in
Speaker 3: Europe as well. The likes of Nova Nordisk, for example,
Speaker 3: have really been selling off this morning in Europe, alongside
Speaker 3: Roche and Santa Fe as well. Nova Nordisk, I should
Speaker 3: mention the ADRs also are available in the United States
Speaker 3: ENVO for that ticker trading out about sixty dollars and
Speaker 3: change down about one point two percent. I'll just mention
Speaker 3: that about sixty percent of Nova Nordisk's revenue comes from
Speaker 3: the United States, so this is a really great spot
Speaker 3: to look at when you're talking about some of the
Speaker 3: movement there in the pharmaceutical space. We're also getting some
Speaker 3: numbers coming out of Walmart, several comments coming from the
Speaker 3: CEO in the last twenty four hours thing that they're
Speaker 3: being focused on keeping price as low, prices as low
Speaker 3: as they possibly can, and really looking at some cost
Speaker 3: cutting measures. They're reaffirming their first quarter sales guidance. In
Speaker 3: their full year twenty twenty six guidance remains unchanged, so
Speaker 3: that's going to be again another major one to watch, Nathan.
Speaker 3: For me, Walmart's WMT is the tell those shares hire
Speaker 3: by two percent this morning.
Speaker 4: The Stock Movers podcast Bloomberg Radio check Back with us
Speaker 4: throughout the day. For the latest roundup of companies making
Speaker 4: news on Wall Street, and for the latest market moving headlines.
Speaker 4: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
Speaker 4: dot com, and on Applecarplay and Android Auto with the
Speaker 4: Bloomberg Business app.